Rivero A - Search Results

1

Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.

Álvarez H, Rava M, Martínez C, Portilla J, Peraire J, Rivero A, Cervero M, Mariño A, Poveda E, Llibre JM; CoRIS Study Group. Álvarez H, et al. Among authors: rivero a. HIV Med. 2022 Sep;23(8):825-836. doi: 10.1111/hiv.13265. Epub 2022 Mar 1. HIV Med. 2022. PMID: 35234328

2

Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.

Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, Torre-Cisneros J, Gomez-Mateos J, Jurado R, Pineda JA. Mira JA, et al. Among authors: rivero a. Am J Trop Med Hyg. 2004 Mar;70(3):298-301. Am J Trop Med Hyg. 2004. PMID: 15031520

3

Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.

Knobel H, Miró JM, Mahillo B, Domingo P, Rivero A, Ribera E, Gonzalez J, Sanz J, González A, Blanco JL, Boix V, Force L, Llibre JM, Dalmau D, Arroyo JA, De la Torre J, Rodriguez D, Montes ML, Arranz A, Sarasa M; Grupo Estudio Syndrome Immunodeficiencies Adquirida 26/02 Study Group. Knobel H, et al. Among authors: rivero a. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1276-81. doi: 10.1097/01.qai.0000137372.18814.34. J Acquir Immune Defic Syndr. 2004. PMID: 15385735 Clinical Trial.

4

A case-control study of HIV patients with the K65R mutation in the reverse transcriptase gene with virological failure.

Palacios R, Viciana I, Lopez-Ruz MA, Rivero A, Ríos MJ, García F, Lozano AB, Nogales MC, Lozano F, Santos J; Kaser Group. Palacios R, et al. Among authors: rivero a. AIDS. 2005 Nov 4;19(16):1928-30. doi: 10.1097/01.aids.0000189865.67182.2c. AIDS. 2005. PMID: 16227808 No abstract available.

5

Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.

Pineda JA, Palacios R, Rivero A, Abdel-kader L, Márquez M, Cano P, Mira JA, Torre-Cisneros J, Lozano F, Santos J. Pineda JA, et al. Among authors: rivero a. J Antimicrob Chemother. 2006 May;57(5):1016-7. doi: 10.1093/jac/dkl074. Epub 2006 Mar 23. J Antimicrob Chemother. 2006. PMID: 16556636 No abstract available.

6

Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.

Palacios R, Vergara S, Rivero A, Aguilar I, Macías J, Camacho A, Lozano F, García-Lázaro M, Pineda JA, Torre-Cisneros J, Márquez M, Santos J. Palacios R, et al. Among authors: rivero a. HIV Clin Trials. 2006 Nov-Dec;7(6):319-23. doi: 10.1310/hct0706-319. HIV Clin Trials. 2006. PMID: 17197379 Clinical Trial.

7

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

Rivero A, Mira JA, Pineda JA. Rivero A, et al. J Antimicrob Chemother. 2007 Mar;59(3):342-6. doi: 10.1093/jac/dkl524. Epub 2007 Jan 25. J Antimicrob Chemother. 2007. PMID: 17255142 Review.

8

[Spanish recommendations for proper use of enfuvirtide].

Ribera E, Moreno S, Viciana P, Echevarría S, Flores J, Francés A, Gómez-Sirvent JL, González J, Hernández-Quero J, Lozano F, Mallolas J, Muñoz A, Ocampo A, Portilla J, Pulido F, Rivero A, Santos J, Soriano V, Antela A, Arazo P, Arribas JR, Cervantes M, Domingo P. Ribera E, et al. Among authors: rivero a. Enferm Infecc Microbiol Clin. 2007 Feb;25(2):131-42. doi: 10.1157/13098573. Enferm Infecc Microbiol Clin. 2007. PMID: 17288910 Review. Spanish.

9

Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.

Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA. Macías J, et al. Among authors: rivero a. Antivir Ther. 2006;11(7):839-46. Antivir Ther. 2006. PMID: 17302246

10

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A. Lopez-Cortes LF, et al. Among authors: rivero a. Ther Drug Monit. 2007 Apr;29(2):171-6. doi: 10.1097/FTD.0b013e31803bb54e. Ther Drug Monit. 2007. PMID: 17417070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

642 results

Search Page